HighTower Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

HighTower Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-11,852	Closed	-$314K	–	2607
2019 Q3	$314K	Sell	11,852 -1,600	-12%	-$44.9K	﹤0.01%	1761
2019 Q2	$360K	Sell	13,452 -564	-4%	-$17.7K	﹤0.01%	1692
2019 Q1	$486K	Sell	14,016 -2,839	-17%	-$81.9K	﹤0.01%	1472
2018 Q4	$330K	Buy	16,855 +2,075	+14%	+$42.7K	﹤0.01%	1561
2018 Q3	$392K	Buy	14,780 +2,805	+23%	+$91.6K	﹤0.01%	1582
2018 Q2	$450K	Buy	+11,975	New	+$458K	﹤0.01%	1496
2018 Q1	–	Sell	-4,565	Closed	-$221K	–	2390
2017 Q4	$221K	Buy	4,565 +520	+13%	+$26.3K	﹤0.01%	1859
2017 Q3	$218K	Buy	+4,045	New	+$237K	﹤0.01%	1853

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

HighTower Advisors's PTLA Position: Q4 2019 in Review

HighTower Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2019, closing a stake of 11,852 shares — an estimated $314K sold.

HighTower Advisors first reported a position in PTLA in Q3 2017 and held it in 8 quarters. The position peaked at $486K in Q1 2019. 224 funds tracked by Wall St. Rank hold PTLA as of Q4 2019.

HighTower Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
HighTower Advisors sold 11,852 Portola Pharmaceuticals, Inc. shares in Q4 2019, an estimated $314K.
HighTower Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q3 2017 and held it in 8 quarters.
HighTower Advisors's Portola Pharmaceuticals, Inc. position peaked at $486K in Q1 2019.
224 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2019.

Based on HighTower Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.